国际肿瘤学杂志

国际肿瘤学杂志 ›› 2012, Vol. 39 ›› Issue (8): 637-640.

• 论著 • 上一篇    下一篇

改良同步后程加速超分割放化疗治疗局部晚期食管鳞癌的临床观察

孙明萍,王冬青,李宝生,孙洪福,魏玉梅,王中堂   

  1. 250117 济南，山东省医学科学院 山东省肿瘤防治研究院放疗六病区
  • 出版日期:2012-08-29 发布日期:2012-08-29
  • 通讯作者: 李宝生，E-mail: baoshli@yahoo.com E-mail:baoshli@yahoo.com
  • 基金资助:

    山东省医药卫生攻关项目（2007HZ102）

Clinical observation of improved late course accelerated hyperfractionated radiotherapy with concurrent chemotherapy for locally advanced esophageal squamous cell carcinoma

SUN  Ming-Ping, WANG  Dong-Qing, LI  Bao-Sheng, SUN  Hong-Fu, WEI  Yu-Mei, WANG  Zhong-Tang   

  1. Department of Radiation Oncology, Shandong Cancer Hospital, Jinan 250017, China
  • Online:2012-08-29 Published:2012-08-29
  • Contact: LI Bao-sheng, E-mail: baoshli@yahoo.com E-mail:baoshli@yahoo.com

PDF

1535

摘要： 目的 探讨改良同步后程加速超分割放疗联合含铂类方案的化疗治疗局部晚期食管鳞癌的疗效和不良反应.方法 68例经病理证实的食管鳞癌患者入组。先行常规分割放疗40 Gy/20次后改行加速超分割放疗1.4 Gy/次，2次/d，间隔≥6 h，照射14次，总剂量59.6 Gy。同步给予以顺铂为基础的联合化疗2个周期，同步放化疗结束后再行2周期化疗。观察患者近期疗效，1、3、5年生存率及治疗相关不良反应。结果 所有患者完成放疗计划，总有效率为91.6%（62/68）。1、3、5年生存率分别为75.5%、46.5%、22.7%。≥3级放射性食管炎的发生率为26.4%；无3级及以上的放射性肺炎发生；放射性皮肤损伤多为0~1级；3级白细胞减少和血小板减少的发生率分别为29.4%和7.4%，4级白细胞减少和血小板减少的发生率均为2.9%。无食管狭窄及严重的肺纤维化发生，有2例（2.9%）出现食管纵隔瘘。结论 改良同步后程加速超分割放化疗治疗局部晚期食管鳞癌疗效满意，治疗相关不良反应发生率降低。

关键词: 食管肿瘤, 放射疗法, 顺铂, 生存率, 不良反应

Abstract: Objective To assess the efficacy and the adverse effects of improved late course accelerated hyperfractionated radiotherapy (LCAHRT) combined with cisplatinbased chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC). Methods 68 Patients with pathologically confirmed ESCC were enrolled. Conventional fractionation was implemented to 40 Gy/20 fractions, followed by LCAHRT delivered 2 fractions of 1.4 Gy with an interval of 6-8 hours per day to 14 fractions, thus the total dose was 59.6 Gy. Two cycles of cisplatinbased chemotherapy were administered concurrently, followed by two more cycles. The shortterm efficacy of treatment, overall survival for 1, 3, 5year, and treatmentrelated toxicity were evaluated. Results All patients successfully completed LCAHRT and the overall response rate was 91.6% (62/68). The overall survival rate of 1, 3, and 5year was 75.5%, 46.5%, 22.7%, respectively. The incidence of radiation esophagitis (grade 3 or greater) was 26.4%, and no patients developed grade 3 or worse radiation pneumonitis. The radiationinduced skin injury were most of grade 0 or 1. Grade 3 of leucopenia and neutropenia were observed in 29.4% and 7.4% of patients, respectively, and grade 4 were both in 2.9%. During longterm followup, no esophageal stenosis and severe pulmonary fibrosis was developed except for two cases(2.9%) of esophageal mediastinal fistula. Conclusion Late course accelerated hyperfractionated radiotherapy combined with chemotherapy yields promising longterm survival, with lower treatmentrelated toxicity for patients of locally advanced esophageal squamous cell carcinoma.

Key words: Esophageal neoplasms, Radiotherapy, Cisplatin, Survival rate, Adverse effects